4 Results for "

urinary calcium excretion

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "urinary calcium excretion" in MCE Product Catalog:

Cat. No.: HY-14401
CAS No.: 787583-71-5
Purity:  99.88%
Synonyms: CLTX-305; JTT-305; MK-5442
Encaleret (CLTX-305) is an orally active antagonist of the calcium-sensing receptor (CaSR), with an IC50 of 12 nM. Encaleret exerts its effect by inhibiting the excessive activity of functional gain-of-function CaSR variants, and can restore blood calcium levels, promote the secretion of parathyroid hormone, improve magnesium and phosphorus metabolism, and increase urinary calcium excretion. Encaleret can be used in the research of diseases such as osteoporosis and autosomal dominant hypocalcemia type 1 .
loading...
    loading...
Cat. No.: HY-W088011B
CAS No.: 2836-32-0
Synonyms: Sodium hydroxyacetate, 98%
Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) is an orally active, versatile organic salt . Sodium glycolate, 98% acts as an enzyme activity regulator that increases the activities of glycolate oxidase (GAO) and lactate dehydrogenase (LDH), while reducing the activity of glycolate dehydrogenase (GAD). Sodium glycolate, 98% induces oxalate biosynthesis and causes hyperoxaluria in rats. Sodium glycolate, 98% reduces urinary calcium excretion in male albino rats. Sodium glycolate, 98% can be used in studies related to calcium oxalate urolithiasis and hyperoxaluria .
loading...
    loading...
Cat. No.: HY-14401B
CAS No.: 787584-62-7
Synonyms: CLTX-305 sodium; JTT-305 sodium; MK-5442 sodium
Research Areas:  

Metabolic Disease

Encaleret (CLTX-305) sodium is an orally active antagonist of the calcium-sensing receptor (CaSR), with an IC50 of 12 nM. Encaleret sodium exerts its effect by inhibiting the excessive activity of functional gain-of-function CaSR variants, and can restore blood calcium levels, promote the secretion of parathyroid hormone, improve magnesium and phosphorus metabolism, and increase urinary calcium excretion. Encaleret sodium can be used in the research of diseases such as osteoporosis and autosomal dominant hypocalcemia type 1 .
loading...
    loading...
Cat. No.: HY-180992
Target:  

Lactate Dehydrogenase

Research Areas:  

Metabolic Disease

Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1 .
loading...
    loading...